These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 22855730)

  • 41. Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats.
    Malendowicz LK; Macchi C; Nussdorfer GG; Nowak KW; Zyterska A; Ziolkowska A
    Int J Mol Med; 2003 Jun; 11(6):763-6. PubMed ID: 12736719
    [TBL] [Abstract][Full Text] [Related]  

  • 42. cAMP-activated protein kinase-independent potentiation of insulin secretion by cAMP is impaired in SUR1 null islets.
    Nakazaki M; Crane A; Hu M; Seghers V; Ullrich S; Aguilar-Bryan L; Bryan J
    Diabetes; 2002 Dec; 51(12):3440-9. PubMed ID: 12453898
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Functional and Metabolomic Consequences of K
    Li C; Ackermann AM; Boodhansingh KE; Bhatti TR; Liu C; Schug J; Doliba N; Han B; Cosgrove KE; Banerjee I; Matschinsky FM; Nissim I; Kaestner KH; Naji A; Adzick NS; Dunne MJ; Stanley CA; De León DD
    Diabetes; 2017 Jul; 66(7):1901-1913. PubMed ID: 28442472
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Restitution of defective glucose-stimulated insulin release of sulfonylurea type 1 receptor knockout mice by acetylcholine.
    Doliba NM; Qin W; Vatamaniuk MZ; Li C; Zelent D; Najafi H; Buettger CW; Collins HW; Carr RD; Magnuson MA; Matschinsky FM
    Am J Physiol Endocrinol Metab; 2004 May; 286(5):E834-43. PubMed ID: 14736703
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.
    Lamont BJ; Li Y; Kwan E; Brown TJ; Gaisano H; Drucker DJ
    J Clin Invest; 2012 Jan; 122(1):388-402. PubMed ID: 22182839
    [TBL] [Abstract][Full Text] [Related]  

  • 46. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals.
    Gasbjerg LS; Helsted MM; Hartmann B; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32077470
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GLP-1 regulates gastroduodenal motility involving cholinergic pathways.
    Schirra J; Nicolaus M; Woerle HJ; Struckmeier C; Katschinski M; Göke B
    Neurogastroenterol Motil; 2009 Jun; 21(6):609-18, e21-2. PubMed ID: 19220754
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
    Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
    Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
    Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biophysical and pharmacological properties of glucagon-like peptide-1 in rats under isoflurane anesthesia.
    Kawano T; Tanaka K; Chi H; Eguchi S; Yamazaki F; Kitamura S; Kumagai N; Yokoyama M
    Anesth Analg; 2012 Jul; 115(1):62-9. PubMed ID: 22504208
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.
    Knauf C; Cani PD; Perrin C; Iglesias MA; Maury JF; Bernard E; Benhamed F; Grémeaux T; Drucker DJ; Kahn CR; Girard J; Tanti JF; Delzenne NM; Postic C; Burcelin R
    J Clin Invest; 2005 Dec; 115(12):3554-63. PubMed ID: 16322793
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
    Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA
    Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
    Kjems LL; Holst JJ; Vølund A; Madsbad S
    Diabetes; 2003 Feb; 52(2):380-6. PubMed ID: 12540611
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo.
    Baggio LL; Kim JG; Drucker DJ
    Diabetes; 2004 Dec; 53 Suppl 3():S205-14. PubMed ID: 15561912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.
    Claus TH; Pan CQ; Buxton JM; Yang L; Reynolds JC; Barucci N; Burns M; Ortiz AA; Roczniak S; Livingston JN; Clairmont KB; Whelan JP
    J Endocrinol; 2007 Feb; 192(2):371-80. PubMed ID: 17283237
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets.
    Fehmann HC; Hering BJ; Wolf MJ; Brandhorst H; Brandhorst D; Bretzel RG; Federlin K; Göke B
    Pancreas; 1995 Aug; 11(2):196-200. PubMed ID: 7479679
    [TBL] [Abstract][Full Text] [Related]  

  • 58. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats.
    Wu L; Olverling A; Huang Z; Jansson L; Chao H; Gao X; Sjöholm Å
    Clin Sci (Lond); 2012 Apr; 122(8):375-84. PubMed ID: 22054347
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action.
    Scrocchi LA; Hill ME; Saleh J; Perkins B; Drucker DJ
    Diabetes; 2000 Sep; 49(9):1552-60. PubMed ID: 10969840
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice.
    Baggio L; Kieffer TJ; Drucker DJ
    Endocrinology; 2000 Oct; 141(10):3703-9. PubMed ID: 11014225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.